ZyVersa Therapeutics
ZVSA
ZVSA was delisted on the 16th of July, 2025.
21 hedge funds and large institutions have $55.4M invested in ZyVersa Therapeutics in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
71.39% more ownership
Funds ownership: 0% → 71.39% (+71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Cohanzick Management
Pleasantville,
New York
|
+$6.92M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$6.92M |
| 3 |
RA
RiverPark Advisors
New York
|
+$6.92M |
| 4 |
Context Capital Management
Lajolla,
California
|
+$4.94M |
| 5 |
Saba Capital Management
New York
|
+$4.69M |
Top Sellers
ZVSA Hedge Fund Activity: Q1 2022 in Review
21 of the 6,362 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q1 2022, worth a combined $55.4M.
Buyers outnumbered sellers: 21 funds opened new ZVSA positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cohanzick Management, opening a new position worth an estimated $6.92M.
- 21 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $55.4M of ZyVersa Therapeutics stock for Q1 2022.
- 21 funds opened new ZyVersa Therapeutics positions in Q1 2022 and 0 closed out, a net change of +21 holders.
- The largest ZyVersa Therapeutics buyer in Q1 2022 was Cohanzick Management, an estimated $6.92M added.
Based on aggregated 13F filings for Q1 2022.